Eisai Showcases Groundbreaking Oncology Research at ESMO 2025 with Long-Term Survival Data

Eisai Showcases Research at ESMO 2025

Eisai Inc., a leader in oncology innovation, is poised to present a series of significant clinical research findings at the upcoming European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, scheduled for October 17-21, 2025. The company’s robust oncology portfolio reflects its commitment to addressing unmet medical needs in cancer treatment, with a particular focus on endometrial carcinoma and renal cell carcinoma.

One of the standout presentations will be from the Phase 3 Study 309/KEYNOTE-775, which investigated the efficacy of lenvatinib (LENVIMA®), an oral multiple receptor tyrosine kinase inhibitor, in combination with pembrolizumab (KEYTRUDA®), a prominent anti-PD-1 therapy from Merck. This study examines its effect on patients diagnosed with advanced endometrial carcinoma. The presentation will include compelling 5-year overall survival data that underscores the long-term effects of this combination therapy.

Dr. Corina Dutcus, the Senior Vice President and Global Clinical Development Lead in Oncology at Eisai, emphasized the significance of these findings, stating, "The 5-year overall survival follow-up from Study 309/KEYNOTE-775 highlights how consistent study data can inform treatment approaches for endometrial cancer. This reflects Eisai's dedication to generating crucial evidence that empowers patients, healthcare providers, and families in their treatment decisions."

In addition to the presentation from the Study 309/KEYNOTE-775, Eisai will unveil research from other key studies in their oncology pipeline. This includes results from the Phase 3 LEAP-001 study, which examines the long-term outcomes of first-line treatment with lenvatinib and pembrolizumab in patients with advanced or recurrent endometrial carcinoma. The company will also unveil results from the final analysis of the CLEAR study in advanced renal cell carcinoma, comparing the combination therapy of lenvatinib plus pembrolizumab against traditional sunitinib treatment.

Furthermore, Eisai plans to highlight innovative pipeline data surrounding E7386, a novel inhibitor targeting CBP/β-catenin interactions, which has demonstrated promising results in preliminary studies. This drug has the potential to offer new options in managing advanced or recurrent endometrial carcinoma when combined with lenvatinib.

The ESMO 2025 Congress provides a vital platform for Eisai to connect with the global oncology community, sharing important advancements in their research intended to promote better treatment outcomes and quality of life for cancer patients. The complete list of Eisai’s research presentations will be available on the ESMO website as the event approaches.

Eisai’s ongoing partnership with Merck has been instrumental in advancing the potential of lenvatinib plus pembrolizumab. This collaboration aims to bring forth significant breakthroughs in cancer therapy, aligning with the companies’ goals to improve patient outcomes in the oncology field.

As Eisai continues its efforts to push boundaries in cancer research, the results presented at ESMO 2025 will not only strengthen existing treatment paradigms but also contribute to advancing new therapies targeting cancers with critical unmet needs. The commitment to innovation and patient-centered research remains at the forefront of Eisai’s mission in human healthcare, as they seek to transform the landscape of cancer treatment for patients everywhere.